M. C. van der Goes

发表

Health care utilisation and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.

J. Jacobs, N. Roodenrijs, P. Welsing, 2021, Rheumatology.

Heat Shock Proteins Can Be Surrogate Autoantigens for Induction of Antigen Specific Therapeutic Tolerance in Rheumatoid Arthritis

W. van Eden, M. C. van der Goes, J. V. van Laar, 2019, Front. Immunol..

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial

P. Welsing, M. C. van der Goes, J. Tekstra, 2022, Trials.

Cortisol During the Day in Patients with Systemic Lupus Erythematosus or Primary Sjögren’s Syndrome

J. Jacobs, R. Geenen, M. C. van der Goes, 2011, The Journal of Rheumatology.

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice

M. Boers, J. Jacobs, J. Kirwan, 2010, Annals of the rheumatic diseases.

Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review.

J. Bijlsma, M. C. van der Goes, G. Valentini, 2013, Clinical and experimental rheumatology.

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

J. Jacobs, J. Bijlsma, P. Welsing, 2012, Osteoporosis International.

The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects

J. Jacobs, J. Bijlsma, M. C. van der Goes, 2014, Arthritis Research & Therapy.

Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph

M. Boers, J. Jacobs, J. Bijlsma, 2015, Arthritis care & research.

EULAR definition of difficult-to-treat rheumatoid arthritis

M. Dougados, D. M. van der Heijde, J. Jacobs, 2020, Annals of the Rheumatic Diseases.

Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

M. Boers, J. Jacobs, J. Kirwan, 2009, Annals of the rheumatic diseases.

Can adverse effects of glucocorticoid therapy be prevented and treated?

J. Jacobs, C. Strehl, F. Buttgereit, 2016, Expert opinion on pharmacotherapy.

Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study.

J. Jacobs, R. Geenen, N. Roodenrijs, 2021, Rheumatology.

Correspondence to viewpoint ‘Defining refractory rheumatoid arthritis’ by Buch

J. Jacobs, N. Roodenrijs, M. C. van der Goes, 2018, Annals of the rheumatic diseases.

Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis

J. Jacobs, J. Bijlsma, M. C. van der Goes, 2016, Current opinion in rheumatology.

Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis

J. Jacobs, C. Strehl, F. Buttgereit, 2017, Expert opinion on investigational drugs.

Intra-articular glucocorticoid injections decrease the number of steroid hormone receptor positive cells in synovial tissue of patients with persistent knee arthritis

J. Jacobs, J. Bijlsma, R. Straub, 2012, Annals of the rheumatic diseases.

Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events.

J. Jacobs, M. C. van der Goes, J. Bijlsma, 2011, Clinical and experimental rheumatology.

Low‐dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy

J. Jacobs, J. Bijlsma, J. Kirwan, 2010, Annals of the New York Academy of Sciences.

Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search

G. Nagy, N. Roodenrijs, P. Welsing, 2022, Rheumatology.

Changes in macrophage inhibitory factor correlate with changes in bone mineral density in glucocorticoid-treated patients with rheumatoid arthritis.

J. Jacobs, J. Bijlsma, M. C. van der Goes, 2011, Rheumatology.

Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma

M. C. van der Goes, H. Bloemendal, R. Klaasen, 2020, Journal of medical cases.

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions

P. Welsing, M. C. van der Goes, J. Tekstra, 2022, Arthritis Research & Therapy.

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

D. Ray, M. Boers, J. Jacobs, 2013, Annals of the rheumatic diseases.

Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease.

J. Jacobs, N. Roodenrijs, P. Welsing, 2020, Rheumatology.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey

M. Dougados, D. M. van der Heijde, J. Jacobs, 2018, Annals of the rheumatic diseases.

Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review.

J. Jacobs, J. Bijlsma, N. Roodenrijs, 2019, Joint, bone, spine : revue du rhumatisme.

Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids

W. Lems, J. Jacobs, P. Welsing, 2011, Annals of the rheumatic diseases.

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

M. Dougados, D. M. van der Heijde, J. Jacobs, 2021, Annals of the Rheumatic Diseases.

Response to: ‘Correspondence on ‘EULAR definition of difficult-to-treat rheumatoid arthritis’’ by Novella-Navarro et al

D. M. van der Heijde, J. Jacobs, G. Nagy, 2020, Annals of the Rheumatic Diseases.

Identifying factors hampering physical activity in longstanding rheumatoid arthritis: what is the role of glucocorticoid therapy?

J. Jacobs, M. C. van der Goes, J. Bijlsma, 2014, Clinical and experimental rheumatology.